tbuckley/cabot-search huggingface dataset:
Improved survival for young acute leukemia patients following a new donor hierarchy for allogeneic hematopoietic stem cell transplantation: A phase <scp>III</scp> randomized controlled study
Authors: Mingming Zhang, Haowen Xiao, Jimin Shi, Yamin Tan, Yanmin Zhao, Jian Yu, Xiaoyu Lai, Yongxian Hu, Weiyan Zheng, Yi Luo, He Huang
Journal: American Journal of Hematology (2021)

The aim of our study was to evaluate the most optimal donor for young acute leukemia (AL) patients with multiple donors available for allogeneic hematopoietic stem cell transplantation (allo-HSCT), including HLA-matched sibling donors (MSDs), HLA-matched unrelated donors (URDs), haploidentical parental donors (HPDs), and haploidentical sibling donors (HSDs). From March 2008 to December 2016, 430 AL patients ≤ 35 years of age were included in the discovery, retrospective study. Patients who received transplantation from a MSD or a HSD had better 5-year OS rates compared with patients who received transplantation from a URD or a HPD. A superior graft-versus-leukemia effect was observed for high-risk patients undergoing HSD-HSCT with a lower relapse rate (p = 0.014) and a higher disease-free survival (DFS) rate (p = 0.029) compared with those undergoing MSD-HSCT. Outcomes of high-risk patients receiving an URD or HPD were equivalent. For intermediate/standard-risk patients, either a MSD or HSD may be the front-line donor selection with comparable outcomes. HLA-matched unrelated donors were preferred over HPDs with reduced non-relapse mortality and higher overall survival (OS) and DFS rates. We further conducted an independent prospective randomized study to evaluate the survival advantage with the new donor hierarchy. Two hundred and fifty patients were randomly assigned to follow our new donor hierarchy or the traditional donor hierarchy at a 2:1 ratio. The new donor hierarchy contributed to significantly superior 2-year OS and DFS rates (OS: 76.2% vs. 67.8%, p = 0.046; DFS: 71.8% vs. 64.5%, p = 0.039).
Extracellular vesicles derived from inflammatory-educated stem cells reverse brain inflammation—implication of miRNAs
Authors: Eleni Markoutsa, Karthick Mayilsamy, Dannielle Gulick, Shyam S. Mohapatra, Subhra Mohapatra
Journal: Molecular Therapy (2021)

Inflammation plays a key role in the development of age-related diseases. In Alzheimer's disease, neuronal cell death is attributed to amyloidbeta oligomers that trigger microglial activation. Stem cells have shown promise as therapies for inflammatory diseases- because of their paracrine activity combined with their ability to respond to the inflammatory environment. However, the mechanisms underlying stem cell-promoted neurological recovery are poorly understood. To elucidate these mechanisms, we first primed stem cells with the secretome of lipopolysaccharide- or amyloidbeta-activated microglia. Then, we compared the immunomodulatory effects of extracellular vesicles (EVs) secreted from primed and non-primed stem cells. Our results demonstrate that EVs from primed cells are more effective in inhibiting microglia and astrocyte activation, amyloid deposition, demyelination, memory loss and motor and anxiety-like behavioral dysfunction, compared to EVs from non-primed cells. MicroRNA (miRNA) profiling revealed the upregulation of at least 19 miRNAs on primed-stem cell EVs. The miRNA targets were identified, and KEGG pathway analysis showed that the overexpressed miRNAs target key genes on the toll-like receptor-4 (TLR4) signaling pathway. Overall, our results demonstrate that priming mesenchymal stem cells (MSCs) with the secretome of activated microglia results in the release of miRNAs from EVs with enhanced immune regulatory potential able to fight neuroinflammation.
Trib1 promotes the development of acute myeloid leukemia in a Ts1Cje mouse model of Down syndrome
Authors: Seiko Yoshino, Miwa Tanaka, Yoshitaka Sunami, Tomoko Takahara, Yukari Yamazaki, Mizuki Homme, Akiko Niibori-Nambu, Motomi Osato, Takashi Minami, Keiichi Ishihara, Takuro Nakamura
Journal: Leukemia (2021)
Cardiac allograft vasculopathy: current review and future research directions
Authors: Jordan S Pober, Sharon Chih, Jon Kobashigawa, Joren C Madsen, George Tellides
Journal: Cardiovascular Research (2021)

Abstract Cardiac allograft vasculopathy (CAV) is a pathologic immune-mediated remodelling of the vasculature in transplanted hearts and, by impairing perfusion, is the major cause of late graft loss. Although best understood following cardiac transplantation, similar forms of allograft vasculopathy occur in other vascularized organ grafts and some features of CAV may be shared with other immune-mediated vasculopathies. Here, we describe the incidence and diagnosis, the nature of the vascular remodelling, immune and non-immune contributions to pathogenesis, current therapies, and future areas of research in CAV.
Recommendations for Age-Appropriate Testing, Timing, and Frequency of Audiologic Monitoring During Childhood Cancer Treatment
Authors: Annelot J. M. Meijer, Marry M. van den Heuvel-Eibrink, Beth Brooks, Antoinette G. am Zehnhoff-Dinnesen, Kristin R. Knight, David R. Freyer, Kay W. Chang, Barbara Hero, Vassilios Papadakis, A. Lindsay Frazier, Claudia Blattmann, Rachael Windsor, Bruce Morland, Eric Bouffet, Stefan Rutkowski, Godelieve A. M. Tytgat, James I. Geller, Lisa L. Hunter, Lillian Sung, Gabriele Calaminus, Bruce C. Carleton, Hiske W. Helleman, Jennifer H. Foster, Mariana Kruger, Richard J. Cohn, Wendy Landier, Martine van Grotel, Penelope R. Brock, Alexander E. Hoetink, Kaukab M. Rajput, Rejin Kebudi, Wim J.E. Tissing, Thomas Lehrnbecher, Marianne D. van de Wetering, L. Lee Dupuis, Paul Rogers, Robert J. Stokroos, Koenraad S. Rhebergen, Ralf A. Boerboom
Journal: JAMA Oncology (2021)

Ototoxicity is an irreversible direct and late effect of certain childhood cancer treatments. Audiologic surveillance during therapy as part of the supportive care pathway enables early detection of hearing loss, decision-making about ongoing cancer treatment, and, when applicable, the timely use of audiologic interventions. Pediatric oncologic clinical practice and treatment trials have tended to be driven by tumor type and tumor-specific working groups. Internationally accepted standardized recommendations for monitoring hearing during treatment have not previously been agreed on.To provide standard recommendations on hearing loss monitoring during childhood cancer therapy for clinical practice.An Ototoxicity Task Force was formed under the umbrella of the International Society of Paediatric Oncology, consisting of international audiologists, otolaryngologists, and leaders in the field of relevant pediatric oncology tumor groups. Consensus meetings conducted by experts were organized, aimed at providing standardized recommendations on age-directed testing, timing, and frequency of monitoring during cancer treatment based on literature and consensus. Consensus statements were prepared by the core group, adapted following several videoconferences, and finally agreed on by the expert panel.The consensus reached was that children who receive ototoxic cancer treatment (platinum agents, cranial irradiation, and/or brain surgery) require a baseline case history, monitoring of their middle ear and inner ear function, and assessment of tinnitus at each audiologic follow-up. As a minimum, age-appropriate testing should be performed before and at the end of treatment. Ideally, audiometry with counseling before each cisplatin cycle should be considered in the context of the individual patient, specific disease, feasibility, and available resources.This is an international multidisciplinary consensus report providing standardized supportive care recommendations on hearing monitoring in children undergoing potentially ototoxic cancer treatment. The recommendations are intended to improve the care of children with cancer and facilitate comparative research on the timing and development of hearing loss caused by different cancer treatment regimens.
カスパーゼ動員ドメイン含有蛋白質14(CARD14)における機能喪失変異はアトピー性皮膚炎の重症変異体と関連する【JST・京大機械翻訳】
Authors: Peled Alon, Sarig Ofer, Sun Guangping, Samuelov Liat, A Ma Chi, Zhang Yuan, Dimaggio Tom, G Nelson Celeste, D Stone Kelly, F Freeman Alexandra, Malki Liron, Vidal Lucia Seminario, M Chamarthy Latha, Briskin Valeria, Mohamad Janan, Pavlovsky Mor, E Walter Jolan, D Milner Joshua, Sprecher Eli
Journal: Journal of Allergy and Clinical Immunology (2019)
Modular design principle based on compartmental drug delivery systems
Authors: Georgios K. Eleftheriadis, Natalja Genina, Johan Boetker, Jukka Rantanen
Journal: Advanced Drug Delivery Reviews (2021)

The current manufacturing solutions for oral solid dosage forms are fundamentally based on technologies from the 19th century. This approach is well suited for mass production of one-size-fits-all products; however, it does not allow for a straight-forward personalization and mass customization of the pharmaceutical end-product. In order to provide better therapies to the patients, a need for innovative manufacturing concepts and product design principles has been rising. Additive manufacturing opens up a possibility for compartmentalization of drug products, including design of spatially separated multidrug and functional excipient compartments. This compartmentalized solution can be further expanded to modular design thinking. Modular design is referring to combination of building blocks containing a given amount of drug compound(s) and related functional excipients into a larger final product. Implementation of modular design principles is paving the way for implementing the emerging personalization potential within health sciences by designing compartmental and reactive product structures that can be manufactured based on the individual needs of each patient. This review will introduce the existing compartmentalized product design principles and discuss the integration of these into edible electronics allowing for innovative control of drug release.
Enforcement of the Physician Payments Sunshine Act
Authors: Eli Y. Adashi, I. Glenn Cohen
Journal: JAMA (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
SO-8 Health-related quality of life in patients treated with pembrolizumab for microsatellite instability-high/mismatch repair deficient advanced solid tumors: Results from the KEYNOTE-158 study
Authors: M. Maio, M. Amonkar, J. Norquist, P. Ascierto, L. Manzyuk, D. Motola-Kuba, N. Penel, P. Cassier, G. Bariani, A. De Jesus Acosta, T. Doi, F. Muñoz, W. Miller, D. Oh, M. Gottfried, R. Wang, K. Norwood, A. Marabelle
Journal: Annals of Oncology (2021)
Doctors have faced “worrying levels of abuse” in past month, BMA reports
Authors: Elisabeth Mahase
Journal: BMJ (2021)

Doctors have faced "worrying levels of abuse" in past month, BMA reports Elisabeth MahaseJust over half (51%) of GPs and 30% of hospital doctors have reported experiencing verbal abuse in the past month, a survey of 2478 doctors and medical students in England, Wales, and Northern Ireland has found.1
Efficacy and safety of inhaled ENaC inhibitor BI 1265162 in patients with cystic fibrosis: BALANCE-CF 1, a randomised, phase II study
Authors: Christopher H. Goss, Isabelle Fajac, Raksha Jain, Wolfgang Seibold, Abhya Gupta, Ming-Chi Hsu, Sivagurunathan Sutharsan, Jane C. Davies, Marcus A. Mall
Journal: European Respiratory Journal (2021)

Background Inhibition of the epithelial sodium channel (ENaC) in cystic fibrosis (CF) airways provides a mutation-agnostic approach that could improve mucociliary clearance in all CF patients. BI 1265162 is an ENaC inhibitor with demonstrated pre-clinical efficacy and safety already demonstrated in humans. Objective We present results from BALANCE-CF TM 1, a phase II, placebo-controlled, randomised, double-blind study of four dose levels of BI 1265162 versus placebo for 4 weeks on top of standard of care in adults and adolescents with CF. Results Initially, 28 randomised subjects (BI 1265162 200 µg twice daily n=14, placebo twice daily n=14) were assessed at an interim futility analysis. Compared with placebo, numerical changes of –0.8% (95% CI –6.6 to 4.9%) in percentage predicted forced expiratory volume in 1s (ppFEV 1 ) and +2.1 units (95% CI –2.4 to 6.5 units) in lung clearance index (LCI) were observed in the active group, meeting a pre-defined stopping rule; accordingly, the study was terminated. Recruitment had continued during the interim analysis and pending results; 24 patients were added across three dose levels and placebo. The final results including these patients (+1.5% ppFEV 1 , 200 µg twice-daily dose versus placebo) were not supportive of relevant clinical effect. Furthermore, LCI change was not supportive, although interpretation was limited due to insufficient traces meeting quality criteria. A 9.4-point improvement in the Cystic Fibrosis Questionnaire – Revised Respiratory Domain was observed in the 200 µg twice daily dose group versus placebo. BI 1265162 up to 200 µg twice daily was safe and well-tolerated. Pharmacokinetics were similar to those in healthy volunteers. Conclusion BI 1265162 was safe, but did not demonstrate a potential for clinical benefit. Development has been terminated.
Two‐year outcomes from the <scp>MitrAl</scp> ValvE Re<scp>paIr</scp> Clinical (<scp>MAVERIC</scp>) trial: a novel percutaneous treatment of functional mitral regurgitation
Authors: Tiffany Patterson, John Gregson, Andrejs Erglis, Jubin Joseph, Ronak Rajani, Karen Wilson, Bernard Prendergast, Stephen Worthley, David Hildick‐Smith, Tony Rafter, Alan Whelan, Federico De Marco, Mark Horrigan, Simon R. Redwood
Journal: European Journal of Heart Failure (2021)
Evaluation of the Merit-Based Incentive Payment System and Surgeons Caring for Patients at High Social Risk
Authors: Jacqueline N. Byrd, Kevin C. Chung
Journal: JAMA Surgery (2021)

The latest step in the Centers for Medicaid & Medicare transformation to pay-for-value is the Medicare Merit-Based Incentive Payment System (MIPS). Value-based payment designs often do not account for uncaptured clinical status and social determinants of health in patients at high social risk, and the consequences for clinicians and patients associated with their use have not been explored.To evaluate MIPS scoring of surgeons caring for patients at high social risk to determine whether this implementation threatens disadvantaged patients' access to surgical care.A retrospective cohort study of US general surgeons participating in MIPS during its first year in outpatient surgical practices across the US and territories. The study was conducted from September 1, 2020, to May 1, 2021. Data were analyzed from November 1, 2020, to March 30, 2021 (although data were collected during the 2017 calendar year and reported ahead of 2019 payment adjustments).Characteristics of surgeons participating in MIPS, overall MIPS score assigned to clinician. and practice-level disadvantage measures. The MIPS scores can range from 0 to 100. For the first year, a score of less than 3 led to negative payment adjustment; a score of greater than 3 but less than 70 to a positive adjustment; and a score of 70 or higher to the exceptional performance bonus.Of 20 593 general surgeons, 10 252 participated in the first year of MIPS. Surgeons with complete patient data (n = 9867) were evaluated and a wide range of dual-eligible patient caseloads from 0% to 96% (mean [SD], 27.1% [14.5%]) was identified. Surgeons in the highest quintile of dual eligibility cared for a Medicare patient caseload ranging from 37% to 96% dual eligible for Medicare and Medicaid. Surgeons caring for the patients at highest social risk had the lowest final mean (SD) MIPS score compared with the surgeons caring for the patients at least social risk (66.8 [37.3] vs 71.2 [35.9]; P < .001).Results of this cohort study suggest that implementation of MIPS value-based care reimbursement without adjustment for caseload of patients at high social risk may penalize surgeons who care for patients at highest social risk.
George Weir Johnston
Authors: Brian Johnston, Peter Crookes
Journal: BMJ (2021)

With a twinkle in his eye, George Weir Johnston liked to describe himself as a gunrunner who imported guns from Russia to Belfast at the height of the Troubles. The gun he personally went to Russia to collect was an SPTU stapling gun, the forerunner to the modern EEA stapling gun widely used for anastomosis in colorectal and oesophageal surgery. He pioneered its use for the stapled transection of the oesophagus, a significant advancement in the management of bleeding oesophageal varices.

George was the youngest of five sons born into a farming family. From a young age, he was determined to pursue a career in medicine rather than …
ステント留置術による分岐部病変に対する生分解性ポリマーベースのバイオマトリックスビオリムス溶出ステント移植後の長期(7年)臨床成績
Authors: Ohya Masanobu, Kadota Kazushige, Hyodo Yusuke, Ohtsuru Suguru, Hasegawa Daiji, Habara Seiji, Tada Takeshi, Tanaka Hiroyuki, Fuku Yasushi, Gotoh Tsuyoshi, Mitsudo Kazuaki
Journal: Circulation (2016)
Unfolded protein response inhibitors cure group A streptococcal necrotizing fasciitis by modulating host asparagine
Authors: Aparna Anand, Abhinay Sharma, Miriam Ravins, Debabrata Biswas, Poornima Ambalavanan, Kimberly Xuan Zhen Lim, Rachel Ying Min Tan, Atul Kumar Johri, Boaz Tirosh, Emanuel Hanski
Journal: Science Translational Medicine (2021)

Inhibiting the formation and release of host asparagine cures invasive group A streptococcal infections in mice.
Recommendations from the EXTRIP workgroup on extracorporeal treatment for baclofen poisoning
Authors: Marc Ghannoum, Ingrid Berling, Valéry Lavergne, Darren M. Roberts, Tais Galvao, Robert S. Hoffman, Thomas D. Nolin, Andrew Lewington, Kent Doi, Sophie Gosselin, Badria Alhatali, Kurt Anseeuw, Steven Bird, Josée Bouchard, Timothy E. Bunchman, Diane P. Calello, Paul K. Chin, David S. Goldfarb, Hossein Hassanian-Moghaddam, Lotte C. Hoegberg, Siba Kallab, Sofia Kebede, Jan T. Kielstein, Joshua D. King, Yi Li, Etienne M. Macedo, Rob MacLaren, Bruno Megarbane, James B. Mowry, Marlies E. Ostermann, Ai Peng, Jean-Philippe Roy, Greene Shepherd, Anitha Vijayan, Steven J. Walsh, Anselm Wong, David M. Wood, Christopher Yates
Journal: Kidney International (2021)
Markedly decreasing azithromycin susceptibility of Neisseria gonorrhoeae, Germany, 2014 to 2021
Authors: Regina Selb, Susanne Buder, Sandra Dudareva, Thalea Tamminga, Viviane Bremer, Sebastian Banhart, Dagmar Heuer, Klaus Jansen
Journal: Eurosurveillance (2021)

We monitored antimicrobial susceptibility developments of Neisseria gonorrhoeae in Germany from January 2014 to May 2021. The proportion of isolates with azithromycin minimum inhibitory concentrations above the epidemiological cut-off increased substantially, from 1.3% in 2014 to 12.2% in 2020. Preliminary data from 2021 showed a further rise (January to May: 20.7%). Therefore, azithromycin as part of the recommended dual therapy in Germany for non-adherent patients is challenged. Antimicrobial susceptibility testing in clinical practice is crucial and continuous susceptibility surveillance indispensable.
RNA sequencing of whole blood reveals early alterations in immune cells and gene expression in Parkinson’s disease
Authors: David W. Craig, Elizabeth Hutchins, Ivo Violich, Eric Alsop, J. Raphael Gibbs, Shawn Levy, Madison Robison, Nripesh Prasad, Tatiana Foroud, Karen L. Crawford, Arthur W. Toga, Timothy G. Whitsett, Seungchan Kim, Bradford Casey, Alyssa Reimer, Samantha J. Hutten, Mark Frasier, Fabian Kern, Tobias Fehlman, Andreas Keller, Mark R. Cookson, Kendall Van Keuren-Jensen, Samantha Hutten, Kendall Van Keuren-Jensen
Journal: Nature Aging (2021)
Cytokine responses in nonlesional psoriatic skin as clinical predictor to anti-TNF agents
Authors: Lam C. Tsoi, Matthew T. Patrick, Shao Shuai, Mrinal K. Sarkar, Sunyi Chi, Bethany Ruffino, Allison C. Billi, Xianying Xing, Ranjitha Uppala, Cheng Zang, Joseph Fullmer, Zhi He, Emanual Maverakis, Nehal N. Mehta, Bethany E. Perez White, Spiro Getsios, Yolanda Helfrich, John J. Voorhees, J. Michelle Kahlenberg, Stephan Weidinger, Johann E. Gudjonsson
Journal: Journal of Allergy and Clinical Immunology (2021)
Abstract 15000: Survival Effect of Beta-Blockers in Patients With Asymptomatic Perioperative Troponin Elevation
Authors: Sandra Shenouda, Abhishek Dutta, Hanumanthu Jogu, Jonathan Brock, Imtiaz Ahmad, Parag A Chevli, Padageshwar Sunkara, Tareq Islam, Chi-Cheng Huang
Journal: Circulation (2019)

Introduction: Asymptomatic troponin (cTnI) elevation in the perioperative period is associated with a high mortality rate. Unlike acute coronary syndrome (ACS), a significant disparity exists in th...
Vaccine effectiveness against SARS-CoV-2 transmission and infections among household and other close contacts of confirmed cases, the Netherlands, February to May 2021
Authors: Brechje de Gier, Stijn Andeweg, Rosa Joosten, Ronald ter Schegget, Naomi Smorenburg, Jan van de Kassteele, Susan JM Hahné, Susan van den Hof, Hester E de Melker, Mirjam J Knol
Journal: Eurosurveillance (2021)

Several studies report high effectiveness of COVID-19 vaccines against SARS-CoV-2 infection and severe disease, however an important knowledge gap is the vaccine effectiveness against transmission (VET). We present estimates of the VET to household and other close contacts in the Netherlands, from February to May 2021, using contact monitoring data. The secondary attack rate among household contacts was lower for fully vaccinated than unvaccinated index cases (11% vs 31%), with an adjusted VET of 71% (95% confidence interval: 63–77).
Vancomycin induced infusion syndrome
Authors: Venkatakrishnan Ramakumar, Balaji Arvind
Journal: BMJ (2021)

This is vancomycin induced infusion syndrome on the back of a man in his 20s (fig 1).



Fig 1 

Vancomycin infusion (500 mg/h) was given to treat Streptococcus viridans infective endocarditis, but 30 minutes after initiation the …
直腸癌における放射線化学療法後のMRI再-病期分類:結果とテクニックの限界
Authors: Fernandez-Gallardo M.T.Martin, Alvarez D.Huerga, Gonzalez M.D.Garcia, Casado A.Ruiz, Mejias V.M.Castellano, Santos D.Gomez, Perez F.Pereira
Journal: Annals of Oncology (2010)